TRV GP IV, LLC
An institutional investment manager in Boston, MA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 10, 2026. SEC CIK 1688325.
- Reported value$253.7m
- Positions2
Holdings: 2 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Maze Therapeutics, Inc.MAZE | COM | 578784100 | 134 | 52.6% | 4,473,958 | Unchanged | |
| Tango Therapeutics, Inc.TNGX | COM | 87583X109 | 120 | 47.4% | 6,374,574 | Unchanged |
Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-340720 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.